Second Sight Medical closes $20m rights offering
Second Sight Medical (NSDQ:EYES) said today it closed a previously announced rights offering, retaining approximately $20.1 million with proceeds slated to support development and improvement of its Argus II retinal prosthesis.
The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the company said.
In the oversubscribed round, Sylmar, Calif.-based offered non-transferable subscription rights to purchase units composed of a share of Second Sight common stock a...
Source: Mass Device - March 9, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news
7 medtech stories we missed: Feb. 17, 2017
[Image from unsplash.com]Several companies released diabetes study results this week, while companies like BioTime closed on their public offerings and Pixium implanted its first bionic eye. Here are 7 medtech stories we missed this week, but were still worth mentioning.
1. Insulet touts glucose control study
Insulet Corp. announced the results from its first feasibility study of its Omnipod Horizon hybrid closed-loop system in a Feb. 17 news release. The positive results showed that the glucose control algorithm performed well and was safe to used day and night for adults who have type 1 diabetes. It also showed that i...
Source: Mass Device - February 17, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Business/Financial News Diabetes Food & Drug Administration (FDA) BioTime FlowAid Medical Technologies Insulet Corporation Medtronic Pixium Vision Polyganics Tandem Diabetes Care Valeritas Holdings Source Type: news
Pixium logs German reimbursement win for Iris II ‘ bionic eye ’
Pixium Vision (EPA:PIX) said today that its Iris II ‘bionic eye’ won NUB 1 reimbursement status from the German Institute for the Hospital Remuneration System.
The company’s epi-retinal implant has 150 electrodes and a bio-inspired camera intended for patients who have lost sight due to retinitis pigmentosa. A computer processes images captured by the camera and transmits the data into a signal, which is then transferred back and projected onto an intraocular implant. The incoming signal stimulates the optic nerve and generates images that the brain can interpret as visual signals.
This status is the hi...
Source: Mass Device - February 14, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Implants Optical/Ophthalmic Prosthetics Wall Street Beat Pixium Vision Source Type: news
Second Sight announces upcoming rights offering
Second Sight Medical (NSDQ:EYES) today released information on an upcoming rights offering, with plans to open on February 10, with proceeds slated to support development and improvement of its Argus II retinal prosthesis.
The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the company said.
In the round, Sylmar, Calif.-based will offer non-transferable subscription rights to purchase units composed of a share of Second Sight common stock and a 5-year warra...
Source: Mass Device - February 6, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news
Second Sight wins German reimbursement for Argus II retinal prosthesis
Second Sight Medical (NSDQ:EYES) said today it won reimbursement coverage for its Argus II epiretinal prosthesis from the German Institute for the Hospital Renumeration System, covering 15 hospitals in the group’s NUB1 innovation program.
The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the company said.
The decision will allow approved hospitals to negotiate reimbursement for treating patients with advanced stage retinitis pigmentosa with the Arg...
Source: Mass Device - February 3, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news
Second Sight Medical wins U.K. reimbursement nod for Argus II ‘ bionic eye ’
Second Sight Medical (NSDQ:EYES) said today that the U.K.’s National Health Service granted reimbursement for the company’s Argus II retinal prosthesis system for blind patients with retinitis pigmentosa.
The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the company said.
The U.K.’s NHS said that “a selective group of severely blind patients with Retinits Pigementosa can have access to the Argus II,” according to Second Sight....
Source: Mass Device - December 22, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news
NHS to fund pioneering bionic eye surgery
Electronic implants will restore some vision to patients with retinitis pigmentosa, an inherited eye disease (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - December 22, 2016 Category: Pharmaceuticals Source Type: news
MassDevice.com +5 | The top 5 medtech stories for November 7, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. First patient receives Pixium bionic vision implant
Pixium Vision said today that the 1st patient in the UK was implanted with its IRIS II bionic vision system.
The epi-retinal implant has 150 electrodes and a bio-inspired came...
Source: Mass Device - November 7, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news
First patient receives Pixium bionic vision implant
Pixium Vision (EPA:PIX) said today that the 1st patient in the UK was implanted with its IRIS II bionic vision system.
The epi-retinal implant has 150 electrodes and a bio-inspired camera intended for patients who have lost sight due to retinitis pigmentosa.
The French company said the implantation and activation was performed in September by principal investigator Dr. Mahi Muqit at Moorfields Eye Hospital. The procedure was done as a part of Pixium’s ongoing, multi-center clinical trial to evaluate the efficacy of IRIS II as a treatment to compensate for blindness and provide greater autonomy for patients.
“T...
Source: Mass Device - November 7, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Implants Neuromodulation/Neurostimulation Optical/Ophthalmic Pixium Vision Source Type: news
Second Sight wins CMS reimbursement codes for Argus II ‘ bionic eye ’
Second Sight Medical (NSDQ:EYES) said today it won reimbursement coverage from the Centers for Medicare & Medicaid Services for procedures using its Argus II retinal prosthesis system designed to restore some vision to blind patients.
The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the company said.
Sylmar, Calif.-based Second Sight Medical said that surgical procedures which include its Argus II will now receive $150,000 from CMS starting in 2017...
Source: Mass Device - November 2, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news
Fuji ’ s Cellular Dynamics launches retinal disease-focused Opsis Therapeutics
Fujifilm Holdings (TSE:4901) company Cellular Dynamics International said today it is launching Opsis Therapeutics, a new venture aiming to develop treatments for patient suffering from retinal diseases.
The newly formed business aims to focus on retinal cell manufacturing and application of regenerative medicines for treating retinal diseases, the company said. CDI made the initial seed investment in Opsis Therapeutics with additional investments slated “as needed” for full-scale development.
“Acquired and inherited diseases of the retina, such as age-related macular degeneration and retinitis pigmentos...
Source: Mass Device - September 28, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Regenerative Medicine Cellular Dynamics International Inc. Fujifilm Holdings Opsis Therapeutics Source Type: news
Researchers identify treatment target for blinding diseases
A common pathway involved in photoreceptor death has been identified in retinitis pigmentosa, advanced dry age-related macular degeneration and other retinal diseases, with early evidence of a possible halt to vision loss related to treatment of the pathway. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 28, 2016 Category: Science Source Type: news
Pixium Vision wins CE Mark for Iris II retinal prosthesis
French retinal implant maker Pixium Vision said Monday it won CE Mark approval in the European Union for its Iris II bionic vision system designed for individuals with vision loss from outer retinal degeneration.
The Iris system is comprised of a retinal implant and a pair of camera-mounted glasses connected to a “pocket computer.” The computer processes images captured by the glasses and transmits the data into a signal that’s transferred back and projected onto the intraocular implant, where it stimulates the optic nerve and generates images that the brain learns to interpret as visual signals.
“The...
Source: Mass Device - July 27, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Optical/Ophthalmic Regulatory/Compliance Pixium Vision Source Type: news
Stem Cell Partnership: Patient Advocates And Scientists At The International Society For Stem Cell Research Convention
STEM CELL PARTNERSHIP: Patient Advocates and Scientists at the International Society for Stem Cell Research Convention
By Don C. Reed
This year's International Society for Stem Cell Researchers (ISSCR) conference was enormous, three vast floors of San Francisco's magnificent Moscone West convention center.
As a watering hole brings animals together, the ISSCR concentrates the world's top stem cell scientists. From around the world they came, four thousand of them this year, representing almost sixty countries. Interspersed with them were patients and patient advocates, those who would benefit most from scientific a...
Source: Science - The Huffington Post - July 8, 2016 Category: Science Source Type: news
Second Sight reels in $19m from oversubscribed rights offering
Second Sight Medical (NSDQ:EYES) said today it raised $19.8 million from an oversubscribed round of rights offering to shareholders of record, with funds slated to support a post-market study of its Argus II retinal prosthesis system.
The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the company said.
Sylmar, Calif.-based Second Sight Medical will float approximately 6 million shares of stock at $3.31 per share, equal to 85% of the closing price of $3.90...
Source: Mass Device - June 1, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news
